发布求助
文献互助 智能选刊 最新文献

CNS Oncology最新文献

筛选
英文 中文
H3G34-mutant diffuse hemispheric glioma with osseous metastases: a case report and literature review. h3g34突变型弥漫性半球胶质瘤伴骨转移1例报告并文献复习。
CNS Oncology Pub Date : 2023-06-01 DOI: 10.2217/cns-2022-0020
Nina Yu, Han Sung Lee, Osama A Raslan, Lee-Way Jin, Orwa Aboud
{"title":"H3G34-mutant diffuse hemispheric glioma with osseous metastases: a case report and literature review.","authors":"Nina Yu,&nbsp;Han Sung Lee,&nbsp;Osama A Raslan,&nbsp;Lee-Way Jin,&nbsp;Orwa Aboud","doi":"10.2217/cns-2022-0020","DOIUrl":"https://doi.org/10.2217/cns-2022-0020","url":null,"abstract":"<p><p><b>Aim:</b> H3G34 diffuse hemispheric glioma is a CNS tumor that is difficult to diagnose and treat and accompanied with poor prognosis. It is becoming clear that extra CNS metastasis may present in a subset of patients with H3G34 gliomas, further complicating diagnosis and treatment. <b>Materials & methods:</b> We present a case of a 19-year-old female with a H3G34 mutant diffuse hemispheric glioma with osseous metastases. We then provide a literature review of the most recent understanding of H3G34 mutant malignancies. <b>Conclusion:</b> Given the stress that patients with H3G34 can experience and the poor prognosis, it is imperative to expand our knowledge and ascertain accurate diagnostic methodologies and targeted therapeutic approaches.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/d7/cns-12-95.PMC10171036.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9612071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report. 老年胶质母细胞瘤患者在西伦吉肽治疗后的长期生存:一例报告。
CNS Oncology Pub Date : 2023-06-01 DOI: 10.2217/cns-2022-0017
Huda Alalami, Serguei Bannykh, Xuemo Fan, Jethro Hu
{"title":"Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report.","authors":"Huda Alalami,&nbsp;Serguei Bannykh,&nbsp;Xuemo Fan,&nbsp;Jethro Hu","doi":"10.2217/cns-2022-0017","DOIUrl":"https://doi.org/10.2217/cns-2022-0017","url":null,"abstract":"<p><p>Glioblastoma (GBM) is the most common malignant brain tumor. Less than 1% of patients survive longer than 10 years. A 77-year-old woman was diagnosed with MGMT-methylated GBM in 2009. The patient received cilengitide as part of the CENTRIC clinical trial in conjunction with standard radiation and chemotherapy. Though the study was halted in 2013, our patient received cilengitide until 2016 with no radiographic evidence of recurrence thus far. This is the oldest reported GBM patient with greater than 10-year survival. Her exceptional response may have been influenced by MGMT promoter methylation status and PTEN expression.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0f/44/cns-12-96.PMC10171035.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9559007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure. 免疫治疗并发皮质类固醇暴露的黑色素瘤脑转移患者的疗效。
CNS Oncology Pub Date : 2023-03-01 DOI: 10.2217/cns-2022-0014
Kathryn R Tringale, Anne S Reiner, Ryka R Sehgal, Katherine Panageas, Allison S Betof Warner, Michael A Postow, Nelson S Moss
{"title":"Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure.","authors":"Kathryn R Tringale,&nbsp;Anne S Reiner,&nbsp;Ryka R Sehgal,&nbsp;Katherine Panageas,&nbsp;Allison S Betof Warner,&nbsp;Michael A Postow,&nbsp;Nelson S Moss","doi":"10.2217/cns-2022-0014","DOIUrl":"https://doi.org/10.2217/cns-2022-0014","url":null,"abstract":"<p><p><b>Aim:</b> Immune checkpoint inhibitor (ICI) efficacy is undefined for melanoma brain metastases (MBM) with concurrent corticosteroid exposure. <b>Materials & methods:</b> We retrospectively evaluated patients with untreated MBM who received corticosteroids (≥1.5 mg dexamethasone equivalent) within 30 days of ICI. mRECIST criteria and Kaplan-Meier methods defined intracranial progression-free survival (iPFS). The lesion size-response association was evaluated with repeated measures modeling. <b>Results:</b> A total of 109 MBM were evaluated. The patient level intracranial response rate was 41%. Median iPFS was 2.3 months and overall survival was 13.4 months. Larger lesions were more likely to progress, with diameter >2.05 cm most predictive of progression (OR: 18.9; 95% CI: 2.6-139.5; p = 0.004). There was no difference in iPFS with steroid exposure pre- versus post-ICI initiation. <b>Conclusion:</b> In the largest reported ICI+corticosteroid cohort, we identify size dependent MBM response.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/58/84/cns-12-93.PMC9996406.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9562397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Intracranial hypotension in a breast cancer patient treated with epidural blood patches. 硬膜外血贴治疗乳腺癌患者颅内低血压1例。
CNS Oncology Pub Date : 2023-03-01 DOI: 10.2217/cns-2022-0019
Marie-Sophie Minot-This, Thomas Grinda, Nicolas Epaillard, David Guyon, Rita El Jawiche, Gabriel Garcia, Barbara Pistilli
{"title":"Intracranial hypotension in a breast cancer patient treated with epidural blood patches.","authors":"Marie-Sophie Minot-This,&nbsp;Thomas Grinda,&nbsp;Nicolas Epaillard,&nbsp;David Guyon,&nbsp;Rita El Jawiche,&nbsp;Gabriel Garcia,&nbsp;Barbara Pistilli","doi":"10.2217/cns-2022-0019","DOIUrl":"https://doi.org/10.2217/cns-2022-0019","url":null,"abstract":"<p><p>We report the case of a patient with metastatic breast cancer who presented with an orthostatic headache. After a comprehensive diagnostic workup including MRI and lumbar puncture, we maintained the diagnosis of intracranial hypotension (IH). The patient was therefore treated with two consecutive non targeted epidural blood patches, resulting in the remission of IH symptoms for 6 months. IH in cancer patients is a rarer cause of headache than carcinomatous meningitis. As the diagnosis can be made by standard examination and the treatment is relatively simple and effective, IH deserves to be better known by oncologists.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/71/cns-12-94.PMC9996407.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9913880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Undesired impact of iron supplement on MRI assessment of post-treatment glioblastoma. 铁补充剂对治疗后胶质母细胞瘤MRI评估的不良影响。
CNS Oncology Pub Date : 2022-12-01 DOI: 10.2217/cns-2021-0018
Dahye Park, Mina Lobbous, Louis B Nabors, James M Markert, Jinsuh Kim
{"title":"Undesired impact of iron supplement on MRI assessment of post-treatment glioblastoma.","authors":"Dahye Park,&nbsp;Mina Lobbous,&nbsp;Louis B Nabors,&nbsp;James M Markert,&nbsp;Jinsuh Kim","doi":"10.2217/cns-2021-0018","DOIUrl":"https://doi.org/10.2217/cns-2021-0018","url":null,"abstract":"<p><p>Glioblastoma (GBM) is the most common malignant adult brain and has a poor prognosis. Routine post-treatment MRI evaluations are required to assess treatment response and disease progression. We present a case of an 83-year-old female who underwent MRI assessment of post-treatment GBM after intravenous iron replacement therapy, ferumoxytol. The brain MRI revealed unintended alteration of MRI signal characteristics from the iron containing agent which confounded diagnostic interpretation and subsequently, the treatment planning. Ferumoxytol injection prior to contrast enhanced MRI must be screened in post-treatment GBM patients to accurately evaluate tumor activity.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/05/4d/cns-11-90.PMC9830595.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10616899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan. 经病理证实的多灶性脑转移瘤对曲妥珠单抗德鲁司坦完全应答。
CNS Oncology Pub Date : 2022-09-01 Epub Date: 2022-06-08 DOI: 10.2217/cns-2022-0010
Nelson S Moss, Umberto Tosi, Bianca D Santomasso, Kathryn Beal, Shanu Modi
{"title":"Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan.","authors":"Nelson S Moss, Umberto Tosi, Bianca D Santomasso, Kathryn Beal, Shanu Modi","doi":"10.2217/cns-2022-0010","DOIUrl":"10.2217/cns-2022-0010","url":null,"abstract":"<p><p>Antibody-drug conjugates have transformed the treatment of HER2+ breast and other cancers. Unfortunately, the CNS remains a sanctuary site for many such patients in part due to poor macromolecule penetration across the blood-brain tumor barrier. Trastuzumab deruxtecan (T-DXd), a high-payload antibody-drug conjugate, was recently found to improve progression-free survival in HER2+ breast cancer patients versus prior-generation trastuzumab emtansine, prompting us to evaluate CNS activity in a woman with brain-only metastatic disease. T-DXd achieved complete response despite heavy pretreatment. Three persistent, previously-irradiated lesions were biopsy-proven to represent treatment effect. Subsequent recurrence occurred upon treatment holiday; partial response was observed with rechallenge. This case suggests T-DXd is active in HER2+ breast cancer brain metastases and supports further prospective evaluation.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72972019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma. 贝珠替凡治疗与冯-希佩尔-林道病相关的中枢神经系统血管母细胞瘤的首次临床经验。
CNS Oncology Pub Date : 2022-07-12 DOI: 10.2217/cns-2022-0008
Andrew Dhawan, David M Peereboom, Glen Hj Stevens
{"title":"First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma.","authors":"Andrew Dhawan, David M Peereboom, Glen Hj Stevens","doi":"10.2217/cns-2022-0008","DOIUrl":"10.2217/cns-2022-0008","url":null,"abstract":"<p><p>We present two cases of von Hippel-Lindau (VHL) disease-associated hemangioblastomas in the CNS treated with the newly approved HIF-2α inhibitor, belzutifan. The first case is a 31-year-old female with confirmed pathogenic germline <i>VHL</i> mutation who presented with multiple hemangioblastomas. The patient was started on belzutifan, and a brisk reduction in perilesional edema was observed after 2 months of treatment. The second patient is a 30-year-old male with familial VHL disease. Imaging revealed multiple cerebellar hemangioblastomas, and follow-up imaging after three cycles of belzutifan revealed a reduction in perilesional edema. Both patients tolerated belzutifan well, with only anemia and fatigue. We highlight our initial experience and early imaging findings associated with belzutifan in VHL disease-associated CNS hemangioblastomas.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40494904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extranodal classical Hodgkin lymphoma involving the spinal cord: case report and review of the literature 结外经典霍奇金淋巴瘤累及脊髓:病例报告及文献回顾
CNS Oncology Pub Date : 2022-06-13 DOI: 10.2217/cns-2021-0011
K. Le Dû, N. Alarion, H. Rabi, O. Casasnovas, P. Robert, Amandine Durand, Bénédicte Burlet, C. Tabouret-Viaud, Selim Ramla, Laurent Martin, C. Rossi
{"title":"Extranodal classical Hodgkin lymphoma involving the spinal cord: case report and review of the literature","authors":"K. Le Dû, N. Alarion, H. Rabi, O. Casasnovas, P. Robert, Amandine Durand, Bénédicte Burlet, C. Tabouret-Viaud, Selim Ramla, Laurent Martin, C. Rossi","doi":"10.2217/cns-2021-0011","DOIUrl":"https://doi.org/10.2217/cns-2021-0011","url":null,"abstract":"Primary CNS involvement is very rare in Hodgkin lymphoma. Here we present two cases of spinal cord dissemination. Two women of 40 and 65 years of age presented symptoms of spinal cord injury; imaging showed an intramedullary mass in T10 and T2, respectively, without vertebral involvement and upper diaphragmatic lymph nodes. Lymph-node biopsy confirmed the diagnosis of classical Hodgkin lymphoma in both patients. The first patient received four cycles of chemotherapy (escalated BEACOPP and ABVD) with intrathecal therapy, and the second four cycles of doxorubicin, vinblastine, dacarbazine (AVD) and local irradiation after surgery decompression. Complete metabolic response was obtained at the end of treatment. After 5 and 7 years of follow-up respectively, neurological deficits persisted in both.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76812257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with delayed diagnosis among Filipino pediatric brain tumor patients: a retrospective review 菲律宾儿童脑肿瘤患者延迟诊断的相关因素:一项回顾性回顾
CNS Oncology Pub Date : 2022-06-09 DOI: 10.2217/cns-2022-0009
P. Orduña, Cheryl Anne P Lubaton-Sacro
{"title":"Factors associated with delayed diagnosis among Filipino pediatric brain tumor patients: a retrospective review","authors":"P. Orduña, Cheryl Anne P Lubaton-Sacro","doi":"10.2217/cns-2022-0009","DOIUrl":"https://doi.org/10.2217/cns-2022-0009","url":null,"abstract":"Aim: Determine delayed diagnosis measured by prediagnostic symptomatic interval (PSI) among Filipino pediatric brain tumor patients and identify associated factors. Methods: Data was collected retrospectively on Philippine General Hospital pediatric brain tumor patients from 2015 to 2019. PSI was calculated. Associated factors were determined. Results: 196 patients were included. Median PSI was 80.5 days. Longer PSI was significantly associated with older age, supratentorial and low-grade tumors, more physician consults prior to subspecialist referral, longer interval from neuroimaging request to facilitation, and those presenting with seizures (11-month delay), poor school performance (1-year delay), behavioral changes (1.3-year delay) and secondary amenorrhea (3-year delay). Conclusion: Delayed diagnosis among Filipino brain tumor patients is associated with age, tumor characteristics and symptoms that are uncommon in this condition. Awareness of these symptoms through physician education, close monitoring of patients, early subspecialist referral and better neuroimaging access may lead to earlier diagnosis.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81652989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Large mirror brain metastases from primary undifferentiated sarcoma of the breast: case report and review of the literature. 乳房原发未分化肉瘤的大镜像脑转移:病例报告及文献回顾。
CNS Oncology Pub Date : 2022-06-01 DOI: 10.2217/cns-2022-0001
Nuno Cubas Farinha, Wilson Teixeira, Diogo Roque, Sergio Livraghi
{"title":"Large mirror brain metastases from primary undifferentiated sarcoma of the breast: case report and review of the literature.","authors":"Nuno Cubas Farinha,&nbsp;Wilson Teixeira,&nbsp;Diogo Roque,&nbsp;Sergio Livraghi","doi":"10.2217/cns-2022-0001","DOIUrl":"https://doi.org/10.2217/cns-2022-0001","url":null,"abstract":"<p><p>Primary breast sarcomas are rare high-grade tumors with a reported incidence of <1% of breast malignancies. Its dissemination to the CNS is exceptional and only one is found in the literature. The authors described the case of a 22-year-old female with history of a breast undifferentiated sarcoma that present with two large bilateral retrolenticular brain metastases. Both lesions were excised in the same procedure and she underwent adjuvant therapy. She died 24 months after surgery. Despite being aggressive lesions, aggressive treatment of primary breast sarcomas including brain metastases excision, should be considered in order to improve overall survival.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b2/f9/cns-11-85.PMC9134969.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10241190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信